Patients with early inflammatory arthritis not meeting classification criteria for rheumatoid arthritis (RA) may have treatment delayed until typical phenotypic features accumulate. Due to the concern for toxicities of DMARDs, patients are often treated with NSAIDs and simple analgesics during this period. However, delay in DMARD treatment in early RA has been shown to result in poorer outcomes, such as irreversible radiographic damage. Addressing this problem, van Dongen et al (Arthritis Rheum 2007; 56(5):1424) report the results of the “PRObable rheumatoid arthritis: Methotrexate vs. Placebo Treatment” (PROMPT) study.

Here is the original post:
PROMPT Study Finds Methotrexate Beneficial in Early Undifferentiated Arthritis

Patients with early inflammatory arthritis not meeting classification criteria for rheumatoid arthritis (RA) may have treatment delayed until typical phenotypic features accumulate. Due to the concern for toxicities of DMARDs, patients are often treated with NSAIDs and simple analgesics during this period. However, delay in DMARD treatment in early RA has been shown to result in poorer outcomes, such as irreversible radiographic damage. Addressing this problem, van Dongen et al (Arthritis Rheum 2007; 56(5):1424) report the results of the “PRObable rheumatoid arthritis: Methotrexate vs. Placebo Treatment” (PROMPT) study.

Follow this link:
PROMPT Study Finds Methotrexate Beneficial in Early Undifferentiated Arthritis

Hydroxychloroquine (Plaquenil) is a commonly used disease modifying anti-rheumatic drug (DMARD) for RA that has known beneficial effects on blood glucose and lipids. However, whether its use can prevent the onset of diabetes in RA patients prescribed it to reduce articular signs and symptoms has not been evaluated. Here, Wasko et al (JAMA 2007; 298: 187) explore this issue using prospective data from the Arthritis, Rheumatism, and Aging Medical Information System (ARAMIS) database.

Go here to see the original:
Hydroxychloroquine Use May Protect Against the Development of Diabetes in RA Patient

Hydroxychloroquine (Plaquenil) is a commonly used disease modifying anti-rheumatic drug (DMARD) for RA that has known beneficial effects on blood glucose and lipids. However, whether its use can prevent the onset of diabetes in RA patients prescribed it to reduce articular signs and symptoms has not been evaluated. Here, Wasko et al (JAMA 2007; 298: 187) explore this issue using prospective data from the Arthritis, Rheumatism, and Aging Medical Information System (ARAMIS) database.

Read the original:
Hydroxychloroquine Use May Protect Against the Development of Diabetes in RA Patient

Todays Leading Edge Business Marketing Solutions & Technologies.

See the rest here:
Christian Times Online